Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              TMS

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data

              Contact the Supplier

              Lead Product(s): TMS-007

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: TMS-007

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Biogen

              Deal Size: $353.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition May 12, 2021

              Details:

              Biogen exercised its option to acquire TMS-007, an investigational drug for acute ischemic stroke, from TMS. Biogen’s decision to acquire TMS-007 was based on positive data from a Phase 2a study.

              PharmaCompass__DigitalAd